Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

abiraterone acetate

National Institute for Health and Care Excellence NICE logo

NICE gives partial backing to Ferring’s prostate cancer drug

Firmagon on course for use on NHS in England and Wales

- PMLiVE

BioAlliance and Topotarget merge to focus on rare cancers

French and Danish firms combine to develop orphan oncology drugs

- PMLiVE

UK cancer awards programme launches

QiC Oncology 2014  announced at ABPI Annual Conference

- PMLiVE

Glioblastomas – a personalised future?

Despite some recent advances treatment remains palliative

- PMLiVE

Lilly thrown a lifeline on US Alimta patent

Court backs protection from generics until 2022

- PMLiVE

GSK halts bid for Votrient maintenance use

Pulls European application for indication in advanced ovarian cancer

- PMLiVE

AZ teams up with UK’s MRC for discovery centre

Public-private facility will be based at the pharma company's Cambridge R&D site

- PMLiVE

AstraZeneca launches delivery service for Nexium

Expands its US direct-to-patient programme

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

- PMLiVE

EMA backs Janssen rare disease drug for approval

Castleman's disease treatment Sylvant wins CHMP recommendation

National Institute for Health and Care Excellence NICE logo

Mixed cancer news from NICE

Agency backs Janssen’s myeloma drug but denies Bayer’s Xofigo in prostate cancer

AstraZeneca to develop mHealth cardiovascular services

Willwork with Vodafone in a new global partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links